Icon Wealth Advisors LLC Reduces Holdings in Novo Nordisk A/S $NVO

Icon Wealth Advisors LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 36.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,527 shares of the company’s stock after selling 13,826 shares during the period. Icon Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,235,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Capital International Investors raised its stake in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after purchasing an additional 969,916 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares in the last quarter. Morgan Stanley raised its position in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Finally, State Street Corp raised its position in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after purchasing an additional 59,153 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the topic of a number of recent analyst reports. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research report on Tuesday, March 3rd. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $43.90 on Monday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $196.02 billion, a price-to-earnings ratio of 10.31, a price-to-earnings-growth ratio of 3.92 and a beta of 0.78. The business has a 50 day simple moving average of $42.28 and a 200-day simple moving average of $46.00.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.